Join us for our BioVenture eLab Speaker Series with a senior leader from Adaptive Biotechnologies

Adaptive Biotechnologies is an early stage company that is viewing the immune system using a combination of DNA sequencing and high-powered computation. They have raised $195 million from investors, and recently concluded a deal with Genentech with a massive $300 million upfront.

Come and hear Dr. Sharon Benzeno, PhD, MBA, Senior Vice President, Research & Business Development of Adaptive Biotechnologies speak about the work they are doing.